Theranostics
13.3
Impact Factor
23.90
CiteScore
< 5 days
First Decision
Global reach, higher impact
Theranostics 2020; 10(16):7406-7408. doi:10.7150/thno.48039 This issue Cite
Erratum
Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum
Maria Tsioumpekou1,2,3*, Sara I. Cunha3,4*, Haisha Ma3,5, Aive Åhgren3, Jessica Cedervall1, Anna-Karin Olsson1, Carl-Henrik Heldin1,3, Johan Lennartsson2,3 
1. Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden.
2. Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
3. Ludwig Institute for Cancer Research, Uppsala Branch, Uppsala University, Sweden.
4. Department of Immunology, Genetics and Pathology, Uppsala University, Sweden.
5. Department of Neuroscience, Uppsala University, Sweden.
* These authors contributed equally to the study.
Published 2020-6-11
Citation:
Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum. Theranostics 2020; 10(16):7406-7408. doi:10.7150/thno.48039. https://www.thno.org/v10p7406.htm
Other stylesCorrected-article in Theranostics, Volume 10, 1122
We noticed an error in figure 5 in our published manuscript [1]. In figure 5 one of the axis in the quantification has been labelled with the wrong marker. Below is a correct version of figure 5.
Figure 5
Selective inhibition of PDGFRβ differentially affects tumor pericyte populations in LLC and B16/PDGF-BB tumors. LLC (A, C, E) and B16/PDGF-BB (B, D, F) tumors were grown in ASKA PDGFRβ mutant mice after treatment with vehicle, 1-NaPP1 or imatinib for 10 consecutive days; sections from tumors were co-immunostained for CD31/podocalyxin and PDGFRβ. PDGFRβ+ pericyte coverage was quantified in LLC (A; CD31, green; PDGFRβ, red) and B16/PDGF-BB (B; podocalyxin, red; PDGFRβ, green). CD31 and α-SMA were co-immunostained and α-SMA+ pericyte coverage quantified in LLC (C) and B16/PDGF-BB (D) tumors (CD31, green; α-SMA, red). Podocalyxin or CD31 and NG2 were co-immunostained and NG2+ pericyte coverage quantified in LLC (E) and B16/PDGF-BB (F) tumors (LLC: CD31, green; NG2, red; B16/PDGF-BB: podocalyxin, red; NG2, green). >20 field 200x magnification images were scored for each mouse (n=5 or more animals). Scale bar, 50 µm. *p<0.05, **p<0.01 and ***p<0.001.
References
1. Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression. Theranostics. 2020;10(3):1122-1135 doi:10.7150/thno.37851
Author contact
Corresponding author: johan.lennartssonuu.se
Citation styles
APA
Tsioumpekou, M., Cunha, S.I., Ma, H., Åhgren, A., Cedervall, J., Olsson, A.K., Heldin, C.H., Lennartsson, J. (2020). Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum. Theranostics, 10(16), 7406-7408. https://doi.org/10.7150/thno.48039.
ACS
Tsioumpekou, M.; Cunha, S.I.; Ma, H.; Åhgren, A.; Cedervall, J.; Olsson, A.K.; Heldin, C.H.; Lennartsson, J. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum. Theranostics 2020, 10 (16), 7406-7408. DOI: 10.7150/thno.48039.
NLM
Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum. Theranostics 2020; 10(16):7406-7408. doi:10.7150/thno.48039. https://www.thno.org/v10p7406.htm
CSE
Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J. 2020. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum. Theranostics. 10(16):7406-7408.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.